Belviq partners up with phentermine

Share this article:

Eisai's experiment with Belviq add-on weight-loss therapy is underway. MedPage Today reports that the two-part medication includes relative weight-loss newcomer Belviq with the older appetite suppressant phentermine, which was part of the disastrous combination weight-loss drug Fen-phen.

Despite the negative connotation, MedPage says the trial mix has been dubbed Belphen. The 12-week trial started in October and was sponsored by drug partners Arena and Eisai.

MedPage says the 225-patient study is a safety trial, and that the impact on weight loss and waist circumference are secondary endpoints. The study does not include a placebo group, nor does it include a echocardiogram, because Belviq's cardiovascular safety profile was sufficient for FDA approval.

The majority of experts told MedPage that they were OK with this study's lack of a cardiovascular component—phentermine was not considered the reason for Fen-Phen's heart damage. However, not everyone is sure this is the smartest way to go.

“This... looks a lot like an opportunity to repeat the dangerous follies of history,” Yale University's Prevention Research Center's David Katz told MedPage.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.